Skip to main content
SpringerLink
Log in

Psoriasisarthritis

Eine bleibende Herausforderung für Rheumatologen und Patienten – Teil 1: Epidemiologie, Pathogenese und Klinik

Psoriatic arthritis

A permanent challenge for rheumatologists and patients – Part 1: epidemiology, pathogenesis and clinical course

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Durch ihre Symptomvielfalt und die damit verbundenen Folgen für den Patienten zählt die Psoriasisarthritis zu einer der großen Herausforderungen in der Rheumatologie. Oft ist bei der Behandlung die fachübergreifende Zusammenarbeit von Allgemeinmedizinern, Dermatologen und Rheumatologen gefragt, die heute aufgrund neuer Klassifikationskriterien wie auch neuer bildgebender Verfahren die Krankheit frühzeitig erkennen und angemessene Therapien einleiten können. Trotzdem stellt die Rückführung des Erkrankungsbeginns auf eine oder mehrere bestimmte Ursachen nach wie vor eine Herausforderung dar, die zusätzlich durch das Fehlen krankheitsspezifischer Serumparameter erschwert wird.

Abstract

Psoriatic arthritis is still one of the big challenges in rheumatology due to the great variety of symptoms. Treatment frequently requires an interdisciplinary collaboration of general practitioners, dermatologists and rheumatologists who are able to recognize the onset of disease early by means of classification criteria and new imaging techniques followed by the implementation of appropriate antirheumatic treatment. During recent years new immunological pathways have been discovered leading to an increasing number of potential therapies, which increases the chance to find effective individualized treatment. However, tracking back the onset of the disease to specific causes is still a challenge which is made even more complex due to the absence of specific serum parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Alibert J (1818) Précis théorique et pratique sur les maladies de la peau. Caille & Ravier, Paris

  2. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–1912

    Article  PubMed  CAS  Google Scholar 

  3. Farber E, Nall M (1998) Epidemiology: natural history and genetics. In: Roenigk H, Maibach H (Hrsg) Psoriasis. Marcel Dekker, New York, S 107–158

  4. Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047

    Article  PubMed  CAS  Google Scholar 

  5. Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441–447

    Article  PubMed  Google Scholar 

  6. Barton AC (2002) Genetic epidemiology. Psoriatic arthritis. Arthritis Res 4:247–251

    Article  PubMed  Google Scholar 

  7. Veale DJ, FitzGerald O (2002) Psoriatic arthritis – pathogenesis and epidemiology. Clin Exp Rheumatol 20(6 Suppl 28):S27–S33

    PubMed  CAS  Google Scholar 

  8. Espinoza LR, Solingen R van, Cuellar ML, Angulo J (1998) Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci 316:271–276

    Article  PubMed  CAS  Google Scholar 

  9. Gladman DD, Farewell VT, Pellett F et al (2003) HLA is a candidate region for psoriatic arthritis: evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64:887–889

    Article  PubMed  CAS  Google Scholar 

  10. Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13:586–592

    PubMed  CAS  Google Scholar 

  11. Espinoza LR, Vasey FB, Gaylord SW et al (1982) Histocompatibility typing in the seronegative spondyloarthropathies: a survey. Semin Arthritis Rheum 11:375–381

    Article  PubMed  CAS  Google Scholar 

  12. Liu Y, Helms C, Liao W et al (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4(3):e1000041

    Article  PubMed  CAS  Google Scholar 

  13. Eastmond CJ, Woodrow JC (1977) The HLA system and the arthropathies associated with psoriasis. Ann Rheum Dis 36:112–120

    Article  PubMed  CAS  Google Scholar 

  14. Gladman DD, Farewell VT, Kopciuk KA, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25:730–733

    PubMed  CAS  Google Scholar 

  15. Chandran V, Gladman DD (2010) Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 12:288–294

    Article  PubMed  CAS  Google Scholar 

  16. Gonzalez S, Martinez-Borra J, Torre-Alonso JC et al (1999) The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 42:1010–1016

    Article  PubMed  CAS  Google Scholar 

  17. Gonzalez S, Brautbar C, Martinez-Borra J et al (2001) Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 62:632–638

    Article  PubMed  CAS  Google Scholar 

  18. Danning CL, Illei GG, Hitchon C et al (2000) Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43:1244–1256

    Article  PubMed  CAS  Google Scholar 

  19. Partsch G, Steiner G, Leeb BF et al (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518–523

    PubMed  CAS  Google Scholar 

  20. Hohler T, Kruger A, Schneider PM et al (1997) A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 109:562–565

    Article  PubMed  CAS  Google Scholar 

  21. Balding J, Kane D, Livingstone W et al (2003) Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48:1408–1413

    Article  PubMed  CAS  Google Scholar 

  22. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA (1999) Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 135:546–552

    Article  PubMed  CAS  Google Scholar 

  23. McQueen FM, Skinner MA, Krissansen GW et al (1994) Natural killer cell function and expression of beta 7 integrin in psoriatic arthritis. J Rheumatol 21:2266–2273

    PubMed  CAS  Google Scholar 

  24. Martin MP, Nelson G, Lee JH et al (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818–2822

    PubMed  CAS  Google Scholar 

  25. Lesage S, Zouali H, Cezard JP et al (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70:845–857

    Article  PubMed  CAS  Google Scholar 

  26. Vermeire S, Wild G, Kocher K et al (2002) CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 71:74–83

    Article  PubMed  CAS  Google Scholar 

  27. Nair RP, Henseler T, Jenisch S et al (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6:1349–1356

    Article  PubMed  CAS  Google Scholar 

  28. Lee FI, Bellary SV, Francis C (1990) Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol 85:962–963

    PubMed  CAS  Google Scholar 

  29. Karason A, Gudjonsson JE, Upmanyu R et al (2003) A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72:125–131

    Article  PubMed  CAS  Google Scholar 

  30. Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii37–ii39; discussion ii40–ii41

    Article  PubMed  Google Scholar 

  31. Trembath RC, Clough RL, Rosbotham JL et al (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813–820

    Article  PubMed  CAS  Google Scholar 

  32. Tomfohrde J, Silverman A, Barnes R et al (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264(5162):1141–1145

    Article  PubMed  CAS  Google Scholar 

  33. Matthews D, Fry L, Powles A et al (1996) Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 14(2):231–233

    Article  PubMed  CAS  Google Scholar 

  34. Capon F, Novelli G, Semprini S et al (1999) Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 112(1):32–35

    Article  PubMed  CAS  Google Scholar 

  35. Enlund F, Samuelsson L, Enerback C et al (1999) Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 7(7):783–790

    Article  PubMed  CAS  Google Scholar 

  36. Lee YA, Ruschendorf F, Windemuth C et al (2000) Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. Am J Hum Genet 67(4):1020–1024

    Article  PubMed  CAS  Google Scholar 

  37. Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38(1):7–13

    Article  PubMed  CAS  Google Scholar 

  38. Zhang XJ, He PP, Wang ZX et al (2002) Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J Invest Dermatol 119(6):1361–1366

    Article  PubMed  CAS  Google Scholar 

  39. Guilhou JJ, Andary M, Clot J (1984) Immunological aspects of psoriasis. VI. Impairment of isoprenaline and theophylline-induced inhibition of mitogen responsiveness. Br J Dermatol 110(4):417–422

    Article  PubMed  CAS  Google Scholar 

  40. Trentham DE, Kammer GM, McCune WJ, David JR (1981) Autoimmunity to collagen: a shared feature of psoriatic and rheumatoid arthritis. Arthritis Rheum 24(11):1363–1369

    Article  PubMed  CAS  Google Scholar 

  41. Krueger GG, Bergstresser PR, Lowe NJ et al (1984) Psoriasis. J Am Acad Dermatol 11(5 Pt 2):937–947

    Article  PubMed  CAS  Google Scholar 

  42. Espinoza LR, Aguilar JL, Espinoza CG et al (1994) Fibroblast function in psoriatic arthritis. I. Alteration of cell kinetics and growth factor responses. J Rheumatol 21(8):1502–1506

    PubMed  CAS  Google Scholar 

  43. Saiag P, Coulomb B, Lebreton C et al (1985) Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 230(4726):669–672

    Article  PubMed  CAS  Google Scholar 

  44. Neumuller J, Dunky A, Burtscher H et al (2001) Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 98:143–152

    Article  PubMed  CAS  Google Scholar 

  45. Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887

    Article  PubMed  CAS  Google Scholar 

  46. Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699–711

    Article  PubMed  CAS  Google Scholar 

  47. Ellis CN, Fradin MS, Messana JM et al (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324:277–284

    Article  PubMed  CAS  Google Scholar 

  48. Murphy FP, Coven TR, Burack LH et al (1999) Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol 135:1495–1502

    Article  PubMed  CAS  Google Scholar 

  49. Gottlieb SL, Gilleaudeau P, Johnson R et al (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442–447

    Article  PubMed  CAS  Google Scholar 

  50. Lebwohl M, Christophers E, Langley R et al (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719–727

    Article  PubMed  CAS  Google Scholar 

  51. Abrams JR, Lebwohl MG, Guzzo CA et al (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–1252

    Article  PubMed  CAS  Google Scholar 

  52. Panayi GS (1994) Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 8:419–427

    Article  PubMed  CAS  Google Scholar 

  53. Costello PJ, Winchester RJ, Curran SA et al (2001) Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 166:2878–2886

    PubMed  CAS  Google Scholar 

  54. Curran SA, FitzGerald OM, Costello PJ et al (2004) Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 172:1935–1944

    PubMed  CAS  Google Scholar 

  55. Tassiulas I, Duncan SR, Centola M et al (1999) Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 60:479–491

    Article  PubMed  CAS  Google Scholar 

  56. Borgato L, Puccetti A, Beri R et al (2002) The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions. J Rheumatol 29:1914–1919

    PubMed  CAS  Google Scholar 

  57. Fassbender HG, Fassbender R (1992) Synovial characteristics of seronegative spondarthritides. Clin Investig 70:706

    Article  PubMed  CAS  Google Scholar 

  58. Espinoza LR, Vasey FB, Espinoza CG et al (1982) Vascular changes in psoriatic synovium. A light and electron microscopic study. Arthritis Rheum 25:677–684

    Article  PubMed  CAS  Google Scholar 

  59. Fearon U, Griosios K, Fraser A et al (2003) Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30:260–268

    PubMed  CAS  Google Scholar 

  60. Ritchlin C, Haas-Smith SA, Hicks D et al (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544–1552

    PubMed  CAS  Google Scholar 

  61. Austin LM, Ozawa M, Kikuchi T et al (1999) The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752–759

    Article  PubMed  CAS  Google Scholar 

  62. Szodoray P, Alex P, Chappell-Woodward CM et al (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46:417–425

    Google Scholar 

  63. McGonagle D, Gibbon W, O’Connor P et al (1998) Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 41:694–700

    Article  PubMed  CAS  Google Scholar 

  64. Laloux L, Voisin MC, Allain J et al (2001) Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60:316–321

    Article  PubMed  CAS  Google Scholar 

  65. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44:2112–2117

    Article  PubMed  CAS  Google Scholar 

  66. Ribbens C, Martin y Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166

    Article  PubMed  CAS  Google Scholar 

  67. Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953

    Article  PubMed  CAS  Google Scholar 

  68. Ritchlin CT, Haas-Smith SA, Li P et al (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831

    PubMed  CAS  Google Scholar 

  69. Suda T, Takahashi N, Udagawa N et al (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357

    Article  PubMed  CAS  Google Scholar 

  70. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176

    Article  PubMed  CAS  Google Scholar 

  71. Udagawa N, Kotake S, Kamatani N et al (2002) The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4:281–289

    Article  PubMed  CAS  Google Scholar 

  72. Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505

    Article  PubMed  CAS  Google Scholar 

  73. Peng H, Wright V, Usas A et al (2002) Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751–759

    PubMed  CAS  Google Scholar 

  74. Stankler L (1969) An experimental investigation on the site of skin damage inducing the Koebner reaction in psoriasis. Br J Dermatol 81:534–535

    Article  PubMed  CAS  Google Scholar 

  75. Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971

    Article  PubMed  CAS  Google Scholar 

  76. Goupille P, Soutif D, Valat JP (1991) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 18:633

    PubMed  CAS  Google Scholar 

  77. Scarpa R, Del Puente A, Girolamo C di et al (1992) Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis 51:78–79

    Article  PubMed  CAS  Google Scholar 

  78. Langevitz P, Buskila D, Gladman DD (1990) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 17:695–697

    PubMed  CAS  Google Scholar 

  79. Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212

    PubMed  Google Scholar 

  80. Rasmussen JE (2000) The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J 19:153–154

    Article  PubMed  CAS  Google Scholar 

  81. Rahman MU, Ahmed S, Schumacher HR, Zeiger AR (1990) High levels of antipeptidoglycan antibodies in psoriatic and other seronegative arthritides. J Rheumatol 17:621–625

    PubMed  CAS  Google Scholar 

  82. Leung DY, Travers JB, Giorno R et al (1995) Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 96:2106–2112

    Article  PubMed  CAS  Google Scholar 

  83. Travers JB, Hamid QA, Norris DA et al (1999) Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest 104:1181–1189

    Article  PubMed  CAS  Google Scholar 

  84. Muto M, Fujikura Y, Hamamoto Y et al (1996) Immune response to Streptococcus pyogenes and the susceptibility to psoriasis. Australas J Dermatol 37(Suppl 1):S54–S55

    Article  PubMed  Google Scholar 

  85. Valdimarsson H, Baker BS, Jonsdottir I et al (1995) Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16:145–149

    Article  PubMed  CAS  Google Scholar 

  86. Zampetti A, Gnarra M, Linder D et al (2010) Psoriatic pseudobalanitis circinata as a post-viral Koebner phenomenon. Case Rep Dermatol 2:183–188

    Article  PubMed  Google Scholar 

  87. Favre M, Orth G, Majewski S et al (1998) Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 110:311–317

    Article  PubMed  CAS  Google Scholar 

  88. Arnett FC, Reveille JD, Duvic M (1991) Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 17:59–78

    PubMed  CAS  Google Scholar 

  89. Brancato L, Itescu S, Skovron ML et al (1989) Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter’s syndrome and related disorders associated with HIV infection. Rheumatol Int 9:137–141

    PubMed  CAS  Google Scholar 

  90. Rashmi R, Rao KS, Basavaraj KH (2009) A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 34:658–663

    Article  PubMed  CAS  Google Scholar 

  91. Tekin NS, Tekin IO, Barut F, Sipahi EY (2007) Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007:78454

    PubMed  Google Scholar 

  92. Yildirim M, Inaloz HS, Baysal V, Delibas N (2003) The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 17:34–36

    Article  PubMed  CAS  Google Scholar 

  93. Rocha-Pereira P, Santos-Silva A, Rebelo I et al (2004) The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150:917–928

    Article  PubMed  CAS  Google Scholar 

  94. Jongh GJ de, Zeeuwen PL, Kucharekova M et al (2005) High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 125:1163–1173

    Article  PubMed  Google Scholar 

  95. Bowes J, Barton A (2010) The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med 10:177–183

    PubMed  Google Scholar 

  96. Brockbank J, Gladman D (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457

    Article  PubMed  CAS  Google Scholar 

  97. Cantini F, Niccoli L, Nannini C et al (2010) Psoriatic arthritis: a systematic review. Int J Rheum Dis 13:300–317

    Article  PubMed  Google Scholar 

  98. Chandran V, Rahman P (2010) Update on the genetics of spondyloarthritis – ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol 24:579–588

    Article  PubMed  CAS  Google Scholar 

  99. Coates LC, Helliwell PS (2010) Disease measurement – enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 24:659–670

    Article  PubMed  Google Scholar 

  100. Mease PJ (2011) Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 70(Suppl 1):i77–i84

    Article  PubMed  Google Scholar 

  101. Rudwaleit M, Taylor WJ (2010) Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Pract Res Clin Rheumatol 24:589–604

    Article  PubMed  Google Scholar 

  102. Lories RJ, Vlam K de, Luyten FP (2010) Are current available therapies disease-modifying in spondyloarthritis? Best Pract Res Clin Rheumatol 24:625–635

    Article  PubMed  Google Scholar 

  103. Maejima H, Taniguchi T, Watarai A, Katsuoka K (2010) Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol 49:901–906

    Article  PubMed  Google Scholar 

  104. Antoni C, Krueger GG, Vlam K de et al (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157

    Article  PubMed  CAS  Google Scholar 

  105. McGonagle D, Lories RJ, Tan AL, Benjamin M (2007) The concept of a „synovio-entheseal complex“ and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 56:2482–2491

    Article  PubMed  Google Scholar 

  106. McGonagle D, Tan AL, Benjamin M (2009) The nail as a musculoskeletal appendage – implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 218:97–102

    Article  PubMed  Google Scholar 

  107. Jamnitski A, Visman IM, Peters MJ et al (2011) Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 70:875–876

    Article  PubMed  CAS  Google Scholar 

  108. Peters MJ, Eijk IC van, Smulders YM et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37:161–166

    Article  PubMed  Google Scholar 

  109. Angel K, Provan SA, Gulseth HL et al (2010) Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55:333–338

    Article  PubMed  CAS  Google Scholar 

  110. Eijk IC van, Peters MJ, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68:362–366

    Article  PubMed  CAS  Google Scholar 

  111. Tam LS, Li EK, Shang Q et al (2011) Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 70:705–706

    Article  PubMed  Google Scholar 

  112. Pischon N, Pischon T, Gulmez E et al (2010) Periodontal disease in patients with ankylosing spondylitis. Ann Rheum Dis 69:34–38

    Article  PubMed  CAS  Google Scholar 

  113. Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874

    Article  PubMed  CAS  Google Scholar 

  114. Skoumal M, Haberhauer G, Fink A et al (2008) Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol 26:1087–1090

    PubMed  CAS  Google Scholar 

  115. Spoorenberg A, Heijde D van der, Klerk E de et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984

    PubMed  CAS  Google Scholar 

  116. Ujfalussy I, Koo E (2003) Measurement of disease activity in psoriatic arthritis. Extended report. Z Rheumatol 62:60–65

    Article  PubMed  CAS  Google Scholar 

  117. Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110

    Article  PubMed  CAS  Google Scholar 

  118. Coates LC, Cook R, Lee KA et al (2010) Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 62:970–976

    Article  Google Scholar 

  119. Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17

    Article  PubMed  Google Scholar 

  120. Helliwell PS, Marchesoni A, Peters M et al (1991) Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Ann Rheum Dis 50:362–365

    Article  PubMed  CAS  Google Scholar 

  121. Laurent MR, Panayi GS, Shepherd P (1981) Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 40:66–69

    Article  PubMed  CAS  Google Scholar 

  122. Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385–390

    Article  PubMed  CAS  Google Scholar 

  123. Mease PJ, Kivitz AJ, Burch FX et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33:712–721

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Klinik III (Rheumatologie & Immunologie), Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland

    S. Finzel

  2. Medizinische Klinik III, Studienambulanz Rheumatologie, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland

    M. Englbrecht

Authors
  1. S. Finzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Englbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S. Finzel or M. Englbrecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finzel, S., Englbrecht, M. Psoriasisarthritis. Z. Rheumatol. 70, 685–697 (2011). https://doi.org/10.1007/s00393-011-0860-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-011-0860-0

Schlüsselwörter

Keywords

Search

Navigation